Florida Cancer Specialists Showcases Pharmacy Integration, Clinical Trial Access
Event summary
- Florida Cancer Specialists & Research Institute (FCS) presented at the NCODA International Spring Forum in Denver on April 15, 2026.
- FCS leaders presented on specialty pharmacy operations, patient navigation, and real-world evidence analysis related to cancer treatment.
- FCS’s in-house specialty pharmacy, ‘Rx To Go,’ exclusively serves patients within the statewide practice.
- FCS has provided patients access to clinical trials, often before FDA approval, positioning them as a leader in oncology research.
The big picture
FCS’s emphasis on integrated pharmacy services and clinical trial access highlights a strategic shift towards value-based care and personalized medicine within the community oncology landscape. The practice’s model, while successful, faces increasing pressure from larger healthcare providers and the rising cost of specialty pharmaceuticals. Their focus on real-world data suggests an attempt to demonstrate clinical and economic value, a critical factor for reimbursement and market positioning.
What we're watching
- Pharmacy Integration
- The success of FCS’s integrated pharmacy model ('Rx To Go') will be a key indicator of whether community oncology practices can effectively compete with larger, vertically integrated healthcare systems.
- Clinical Trial Access
- The continued ability of FCS to offer clinical trials before FDA approval will depend on maintaining strong relationships with pharmaceutical companies and navigating evolving regulatory pathways.
- Real-World Data
- The utility of FCS’s real-world evidence analysis, particularly concerning Zanubrutinib, will determine its ability to influence treatment protocols and potentially attract further research funding.
Related topics